CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NON-ADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/MIXED EPISODE OF BIPOLAR DISORDER- RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY
Author(s)
Hong J1, Reed C2, Novick D2, Haro JM3, Aguado J31London School of Economics, London, United Kingdom, 2Eli Lilly and Company, Windlesham, Surrey, United Kingdom, 3Sant Joan de Deu-SSM, Barcelona, Spain
Presentation Documents
OBJECTIVES: To investigate the consequences of medication non-adherence on relapse, recurrence, remission and recovery, and to estimate costs associated with non-adherence over 21-months in the treatment of bipolar disorder following a manic or mixed episode. METHODS: EMBLEM is a prospective, observational study on patient outcomes with a manic/mixed episode. Data was collected at baseline, during the first 12 weeks of treatment (acute phase), at 6 month post-baseline and at 6-month intervals up to 24 months (maintenance phase). Medication adherence was assessed at each visit by investigators as: i) not prescribed medication; ii) almost always adheres; iii) adheres half of the time; and iv) never adheres to medication. Adherence was defined as always answering ‘always adheres’ and non-adherence was defined when one or more response of ‘adheres half of the time’ or ‘never adheres’. In this post-hoc analysis, Cox proportional hazards models with non-adherence, adjusted for patient characteristics, investigated its impact on clinical outcomes. Multivariate analyses were performed to estimate the cost of resource use associated with non-adherence during the maintenance phase, using a log-link function. UK unit costs were applied to resource use. RESULTS: Of the 1341 patients analysed, 23.6% were non-adherent over 21-months. Non-adherence was significantly associated with a higher risk of relapse (HR:2.40, 95%CI:2.04-2.83) and recurrence (HR:1.72, 95%CI:1.27-2.33) as well as lower remission rates (Hazard ratio (HR):0.71, 95%CI:0.59-0.86) and recovery (HR:0.65, 95%CI:0.51-0.81). In addition, costs incurred by non-adherent patients during this period were significantly higher than those of adherent patients (£10231 vs. £7379). This disparity resulted mainly from differences in in-patient costs (£4796 vs. £2150). CONCLUSIONS: Non-adherence in bipolar patients after a manic/mixed episode is associated with higher than twice the risk of relapse of adherent patients which has economic implications for healthcare providers. A study limitation is that adherence was assessed by investigators using a single-item measure.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PMH25
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health